Treatment of glucocorticoid induced hyperglycemia in patients with type 2 diabetes mellitus with omarigliptin at Okayama university hospital: an open label randomized controlled trial

Treatment of glucocorticoid induced hyperglycemia in patients with type 2 diabetes mellitus with omarigliptin at Okayama university hospital: an open label randomized controlled trial - Good-MOMO study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026022

Enrollment

Registered

2017-04-19

Start date

2017-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Omarigliptin Standard therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Prednisolone >=15mg/day will be taken 2) Type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetes mellitus 2) Concomitant glucocorticoid pulse therapy 3) Treated with insulin or dipeptidyl peptidase-4 inhibitor 4) Malignancy 5) Pregnant or breastfeeding 6) Difficulty in taking pills 7) Autoimmune pancreatitis 8) Patients who are considered as inappropriate for attending this study by their physicians

Design outcomes

Primary

Measure	Time frame
The proportion of patients who were treated with insulin or whose plasma glucose levels elevated above 200mg/dL	—

Secondary

Measure	Time frame
1) Insulin therapy 2) Other treatments of DM 3) Adverse events 4) HbA1c 5) Glycoalbumin 6) 1,5-AG	—

Countries

Japan

Contacts

Public ContactKen-ei Sada

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism

sadakenn@md.okayama-u.ac.jp+81-86-222-5214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026